年別の研究成果
年別の研究成果
研究成果
- 5 Article
検索結果
-
2022
An Empirical Analysis of Japan's Drug Development Lag Behind the United States
Nakamura, H., Wakutsu, N., Murayama, S. & Suzuki, T., 2022 7月, In: Journal of Clinical Pharmacology. 62, 7, p. 847-854 8 p.研究成果: Article › 査読
1 被引用数 (Scopus) -
2020
Reducing Reimbursement Drug Price Risk to Enhance R&D Incentives without Raising Drug Prices/Expenditures: Implications of Simulations Based on Questionnaire Survey of Pharmaceutical Companies in Japan
Nakamura, H. & Wakutsu, N., 2020 7月, In: Health Policy. 124, 7, p. 714-720 7 p.研究成果: Article › 査読
1 被引用数 (Scopus) -
2019
Reducing pharmaceutical reimbursement price risk to lower national health expenditures without lowering R&D incentives
Nakamura, H. & Wakutsu, N., 2019 1月 31, In: International Journal of Economic Policy Studies. 13, 1, p. 75-88 14 p.研究成果: Article › 査読
1 被引用数 (Scopus) -
2012
Outcomes-based risk-sharing schemes: Is there a potential role in the Asia-Pacific markets?
Coulton, L., Annemans, L., Carter, R., Herrera, M. B., Thabrany, H., Lim, J., Lee, K. K. C., Chen, W., Chaiyakunapruk, N., Chern, H. D., Lee, T. J., Nakamura, H., Tarn, T. Y. H. & Keskinaslan, A., 2012 11月, In: Health Outcomes Research in Medicine. 3, 4, p. e205-e219研究成果: Article › 査読
8 被引用数 (Scopus) -
2010
Firms' open innovation policies, laboratories' external collaborations, and laboratories' R&D performance
Asakawa, K., Nakamura, H. & Sawada, N., 2010 3月 1, In: R and D Management. 40, 2, p. 109-123 15 p.研究成果: Article › 査読
59 被引用数 (Scopus)